Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
72
GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
Placebo s.c. daily for 26 weeks
Dept. of Medicine and Dept. of Gyn-Obs, Herlev Hospital
Herlev, Denmark
Herlev Hospital, Dept of Gynecology
Herlev, Denmark
Dept. of Medicine and Dept. of Obstetrics and Gynaecology, Herlev Hospital
Herlev, Denmark
Change in Endogenous Thrombin Potential (ETP)
Area under curve in a Thrombin Generation Test (TGT). Measurements every min for 10 min
Time frame: at time 0 and 26 weeks
Percent Change in Plasma Level of Plasminogen Activator Inhibitor -1 PAI-1
Time frame: at time 0 and 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.